← Leaderboards
Roderick Tang
Meissa Vaccines, Inc.
$889,900
Attributed
$1,779,800
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $999.7K · FY2017–19$1M$750K$500K$250K$0
'17
'18
'19
Funding mix
By agency
NIH$1,779,800 · 2
By mechanism
R44$1,563,412 · 1
R43$216,388 · 1
Top collaborators
- Martin Lawrence Moore4 shared
Others in their field
Other Emerging Leaders on “Virus”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,525,404
- Leonard Freedman · Leidos Biomedical Research, Inc.$79,828,969
- Ted Ross · University Of Georgia$71,962,304
- Beth Baseler · Leidos Biomedical Research, Inc.$67,833,289
- Tony Moody · Duke University$66,767,417
- Matthew Johnson · Duke University$61,899,930
Research focus
VirusHospitalizationPreparationVaccinesSeedsImmunogenicityImmunityIn VitroSerumCyclic GmpCgmp ProductionBaseProteinsInnovationEquilibriumAntigensClinical TrialsCodon NucleotidesAnimalsCohortElectroporationEpithelialClinical ResearchAblation
Grant awards (4)
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$339,597
R44 · FY2019 · AI · contact PI
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$999,722
R44 · FY2018 · AI · contact PI
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$224,093
R44 · FY2017 · AI · contact PI
Development of polyvalent inactivated rhinovirus vaccine$216,388
R43 · FY2017 · AI · contact PI